Protagonist Therapeutics (PTGX) Cash Flow: Operating & Free Cash Flow

Protagonist Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Protagonist Therapeutics, Inc. (PTGX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Operating Activities
Net Income	0.00	275.19	-78.96	-127.39	-125.55	-66.15	-77.19	-38.92	-36.96
Depreciation & Amortization	0.00	2.90	0.98	1.03	0.81	2.72	2.50	0.53	0.41
Deferred Income Tax	0.00	0.00	0.00	0.00	0.00	1.44	-0.78	-0.66	0.00
Stock Based Compensation	45.97	37.55	29.29	24.20	16.40	7.90	8.35	6.92	4.24
Change in Working Capital	146.21	-122.61	-19.51	-7.77	-3.31	-19.02	26.14	-18.02	35.56
Change in Accounts Receivable	164.88	-155.00	-9.99	4.24	-0.92	4.33	-0.76	-2.77	-1.82
Change in Inventory	0.00	0.00	0.00	-4.24	0.92	-3.34	0.76	3.85	5.53
Change in Accounts Payable	3.72	0.84	-2.93	1.22	-3.22	0.31	-3.00	4.43	0.09
Change in Other Working Capital	-22.39	31.55	2.53	2.34	-5.40	3.40	29.14	-23.53	31.75
Other Operating Activities	-134.51	-8.88	2.53	2.34	3.79	2.02	-0.56	0.21	0.63
Net Cash from Operating Activities	57.67	184.15	-70.24	-108.14	-107.87	-72.48	-41.53	-49.95	3.87
Investing Activities
Capital Expenditures	-1.59	-1.36	-0.61	-0.80	-1.10	-0.47	-0.97	-0.49	-0.67
Acquisitions	0.00	0.00	0.00	-91.47	14.76	90.49	52.74	0.00	0.00
Purchases of Investments	-546.59	-621.70	-191.05	-214.87	-286.59	-90.49	-166.94	-71.06	-39.55
Sales/Maturities of Investments	498.84	323.57	152.40	307.14	271.83	189.53	114.19	73.76	56.04
Other Investing Activities	0.00	0.00	0.00	91.47	-14.76	-90.49	-52.74	2.70	16.49
Net Cash from Investing Activities	-49.33	-299.48	-39.26	91.47	-15.86	-90.97	-53.71	2.21	15.82
Financing Activities
Debt Repayment	0.00	0.00	0.00	0.00	0.00	-10.52	9.77	0.00	0.00
Common Stock Issued	23.34	26.45	132.10	14.55	130.11	258.16	34.49	23.18	64.55
Common Stock Repurchased	0.00	0.00	-0.77	-0.19	-0.19	0.00	0.00	0.00	0.00
Other Financing Activities	-0.48	-0.60	-0.77	-0.16	6.09	-0.01	1.78	0.93	1.01
Net Cash from Financing Activities	22.86	25.85	170.48	18.84	129.92	247.63	46.04	24.12	65.55
Summary
Effect of Forex Changes on Cash	-0.06	0.00	0.00	-0.09	-0.13	0.18	-0.03	-0.18	0.15
Net Change in Cash	31.14	-89.48	60.98	2.08	6.07	84.35	-49.23	-23.80	85.40
Cash at Beginning of Period	97.25	186.95	125.97	123.89	117.82	33.47	82.69	106.49	21.09
Cash at End of Period	128.39	97.47	186.95	125.97	123.89	117.82	33.47	82.69	106.49
Free Cash Flow	56.08	182.80	-70.85	-108.93	-108.97	-72.96	-42.49	-50.43	3.21
Supplemental Disclosures
Interest Paid	-	-	-	-	-	0.44	-	-	-
Income Taxes Paid	-	1.53	-	-	-	-	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Protagonist Therapeutics Cash Flow

What is Protagonist Therapeutics's free cash flow?

Protagonist Therapeutics generated free cash flow of $56.08M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $57.67M minus $1.59M of capital expenditures. That was down 69.3% from $182.80M a year earlier. Free cash flow equaled 121.9% of revenue.

How much does Protagonist Therapeutics spend on capital expenditures?

Protagonist Therapeutics spent $1.59M on capital expenditures in fiscal 2025, compared with $1.35M a year earlier. That equals 2.8% of operating cash flow.

Does Protagonist Therapeutics pay dividends or buy back shares?

Protagonist Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition